[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.247.205. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 6, 1954

CLINICAL EVALUATION OF PRIMIDONE (MYSOLINE), NEW ANTICONVULSANT DRUG

Author Affiliations

New York

From the Department of Neurology, College of Physicians and Surgeons, Columbia University, and the Neurological Institute, Presbyterian Hospital.

JAMA. 1954;154(10):827-829. doi:10.1001/jama.1954.02940440025007
Abstract

An appreciable number of patients with seizures are not helped by the standard anticonvulsants. There is, therefore, a constant search for new agents that will benefit this group. A new synthetic compound, primidone (Mysoline), has been made available to a number of investigators, and the results of four separate clinical trials had been reported at the time of writing.1 Handley and Stewart1a found this drug to be effective in 80% of 40 patients with grand mal seizures. In Butler's series1b of 58 patients with all types of seizures, there was improvement in 50% of patients with grand mal attacks. Smith and McNaughton1c were able to evaluate the results of primidone therapy in 61 patients and found that 35% were improved. Bonkalo and Arthurs1d reported on the use of primidone in the treatment of epileptic and nonepileptic psychiatric patients. They noted a reduction in the seizure

First Page Preview View Large
First page PDF preview
First page PDF preview
×